INTRODUCTION
The Sleep-Disordered Breathing (SDB) which is generally classified into Obstructive Sleep Apnea (OSA) and Central Sleep Apnea (CSA), has been reported in 6.5 to 9 percent of adults (1) .
Despite the lower prevalence of CSA rather than OSA (2) , CSA syndromes can be categorized into five subsets: primary (idiopathic) CSA, CSA due to Cheyne-Stokes breathing, CSA due to medical disorder without CheyneStokes breathing, high-altitude periodic breathing and CSA due to drug or substance (3, 4) .
To verify this categorization, some studies indicated increased risk of OSA due to opioids (5, 6) . For examples 75% of opioid users had experienced more than 5 apneic TANAFFOS Amra B, et al. 65 Tanaffos 2018; 17 (3) : [155] [156] [157] [158] [159] [160] [161] [162] episodes per hour of sleep (7) and/or 30% of cancer patients using opioids to manage the pain, were dealt with increased CSA episodes (8) .
Given chronic opioid users response to hypercapnia through a depressed ventilation versus their augmented response to hypoxia, the lack of regulation about respiratory chemical reactions may lead to an instable breathing (9, 7, 10) . Hence, some studies have pointed out that sleep apneas could be the cause of mortality induced by over-use of opioids (11, 12) . However, unfortunately CSA treatment in opioids addicts is rarely investigated (4, 13) .
Taking into account the concerns about uncontrollable pain and/or increased desire to use opioids, perhaps decreased dosage of opioids cannot be considered as an easy solution to treat (14) . Applied treatment options from 2007 so far, including Positive Airway Pressure (PAP) (14) , servoventilation (ASV) (15, 16) , Continuous Positive Airway Pressure (CPAP) (7), BPAP+O2 or CPAP+O2, as a single therapy or step-by-step were used to achieve the desired response (17), although Farney et al. reported no improvement in ataxic breathing and overnight oxygenation in addicted CSA patients using ASV (18) .
Thus, given the purity of evidence in literature evaluating the efficacy of available CSA therapies, the lack of similarity of these therapies can be anticipated (19, 20) .
The contradictory results can be attributed to different definitions of CSA, therapeutic conditions and procedures as well as opioids dosage and medical conditions (4) .
Given increasing opioid use worldwide, the role of etiologies as well as concomitants in therapy choice and the lack of a global standard treatment; the current study aimed to evaluate some therapy options in CSA with respect to the histories of concomitants and opioid use in the patients.
MATERIALS AND METHODS
This longitudinal cross-sectional study aimed to compare therapeutic approaches to CSA in addicts. Taking As shown, 17 patients were responsive to CPAP versus 24 nonresponsive patients. There were significant difference between these patients in mean AHI and smoking (P value<0.05). The majority of nonsmoking addicts with rather high degree of AHI were more responsive to CPAP. Moreover, the addiction course among these CPAP responders (mean addiction course=9.71±2.64y) was significantly shorter than nonresponsive patients to CPAP (mean addiction course=11.50±2.62y) (P value=0.038) ( Table 2) . In this regard, the prevalence of CSA is considerably higher in men and it increases with age. For example a community cohort of 741 men showed that the CSA prevalence was estimated to be 0.4% overall among those aged 65 and older (22) . Also, afterwards another cohort of 2,911 men reported that the CSA prevalence (CAI ≥ 5) was higher among those aged 65 and older (23) . Many studies have reported that opioid use is common in CSA patients and these patients may be at risk of death, whereas their mortality rate has been estimated to be 3% (24) . and 2009, using PAP as a therapeutic approach for chronic opioids users with CSA was successful (15, 25) . In 2012, two larger studies were conducted to treat CSA as well (17, 26) .
RESULTS

This
The results of these two studies suggested success of using ASV to treat CSA in association with opioids in 59.6% of cases (26) . Another study including 151 patients with CSA, of which 41 patients were opioid addicts, showed that the success of CPAP, CPAP + O2 and BPAP + O2 based on a step-by-step protocol were 54%, 27% and 10%, respectively; thus, using CPAP as the primary choice and CPAP+O2 as the second choice for treatment of this group of patients were recognized (17) .
On the other hand, the assessment of patients' condition impact on responsiveness to therapeutic approaches in the current study showed that the majority of CPAP responders were not smokers but with a rather high AHI. Also, this therapy for patients with longer addiction course was unsuccessful. Then, using CPAP+O2 was successful only for patients with a lower AHI, while addiction course could not play a determinant role in their responsiveness. Finally, of 18 remained patients, 16 cases were responsive to BPAP versus two nonresponsive patients who were discharged after oxygen administration.
There was no difference between these patients in terms of In this regard, many studies have supported the effect of CPAP on CSA (17, 24, 27, 28) . In the literature it has been reported that CPAP without oxygen supplement was ineffective in three patients with a long-run use of opioids and only it can slightly prevent hypoxemia (33) .
Also, some studies have pointed out that ASV and BPAP are more expensive than CPAP and in some cases without desired response. Thus, the practical approach can be still using CPAP as the primary therapy, although ASV and BPAP can be applied as alternatives if CPAP failed (9, 25, 26) . Given the various presentations of CSA and its association with opioids use and variations in reactions to opioids (7, 34) , using a medical approach with paying attention to individual characteristics (e.g. overnight hypoxemia, CSA, awaking reactions, daytime sleepiness/consciousness and so on) can be more rational and safer approach.
Therefore, further RTC studies with larger sample size are recommended to compare basic and clinical outcomes of CPAP and other therapies. Furthermore, lack of longrun patients' follow-up after treatment is one of the limitations of this study. Thus, it is suggested to follow-up patients for a longer period of time in further studies with a similar staged protocol and conduct independent studies to evaluate two-by-two these approaches to provide more appropriate documented results using larger sample size.
